The assessment of methylated BASP1 and SRD5A2 levels in the detection of early hepatocellular carcinoma

International Journal of Oncology

Volumn 36, Issue 1, 2010, Pages 205-212

  Tsunedomi, Ryouichi ^a   Ogawa, Yasushi ^a   Iizuka, Norio ^a,b   Sakamoto, Kazuhiko ^a   Tamesa, Takao ^a   Moribe, Toyoki ^c   Oka, Masaaki ^a  

^a YAMAGUCHI UNIVERSITY   (Japan)

^b YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Research Group   (Japan)

Author keywords

BASP1; Hepatocellular carcinoma; Methylation; SRD5A2

Indexed keywords

ALPHA FETOPROTEIN; BRAIN ABUNDANT MEMBRANE ATTACHED SIGNAL PROTEIN 1; MEMBRANE PROTEIN; STEROID 5ALPHA REDUCTASE 2; TUMOR MARKER; UNCLASSIFIED DRUG;

ACETYLATION; ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER SIZE; CANCER STAGING; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DIAGNOSTIC ACCURACY; DNA FLANKING REGION; DNA METHYLATION; EARLY CANCER; EARLY DIAGNOSIS; FEMALE; GENE CONTROL; GENE LOCUS; GENETIC EPIGENESIS; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER CELL CARCINOMA; MALE; ONCOGENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; TUMOR DIFFERENTIATION;

AGED; CARCINOMA, HEPATOCELLULAR; CPG ISLANDS; DNA METHYLATION; DNA PRIMERS; EPIGENESIS, GENETIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 74549131213     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000491     Document Type: Article

References (41)

1. El-Serag HB and Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745-750, 1999.
2. Okuda K: Hepatocellular carcinoma. J Hepatol 32: 225-237, 2000.
3. Esteller M, Corn PG, Baylin SB and Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229, 2001.
4. Jones PA and Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428, 2002.
5. Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054, 2003.
6. Dammann R, Li C, Yoon JH, Chin PL, Bates S and Pfeifer GP: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25: 315-319, 2000.
7. Jin Z, Tamura G, Tsuchiya T, Sakata K, Kashiwaba M, Osakabe M and Motoyama T: Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers. Br J Cancer 85: 69-73, 2001.
8. Song JZ, Stirzaker C, Harrison J, Melki JR and Clark SJ: Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene 21: 1048-1061, 2002.
9. Ku JL, Kang SB, Shin YK, Kang HC, Hong SH, Kim IJ, Shin JH, Han IO and Park JG: Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene 23: 6736-6742, 2004.
10. Yu J, Zhang HY, Ma ZZ, Lu W, Wang YF and Zhu JD: Methylation profiling of twenty four genes and the concordant methylation behaviors of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell Res 3: 319-333, 2003.
11. Lehmann U, Berg-Ribbe I, Wingen LU, Brakensiek K, Becker T, Klempnauer J, Schlegelberger B, Kreipe H and Flemming P: Distinct methylation patterns of benign and malignant liver tumors revealed by quantitative methylation profiling. Clin Cancer Res 11: 3654-3660, 2005.
12. Moribe T, Iizuka N, Miura T, Stark M, Tamatsukuri S, Ishitsuka H, Hamamoto Y, Sakamoto K, Tamesa T and Oka M: Identification of novel aberrant methylation of BASP1 and SRD5A2 for early diagnosis of hepatocellular carcinoma by genome-wide search. Int J Oncol 33: 949-958, 2008.
13. Wilcox CB, Baysal BE, Gallion HH, Strange MA and DeLoia JA: High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet 159: 114-122, 2005.
14. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV and Laird PW: Methylight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28: E32, 2000.
15. Tsunedomi R, Iizuka N, Yamada-Okabe H, Tamesa T, Okada T, Sakamoto K, Takashima M, Hamaguchi T, Miyamoto T, Uchimura S, Hamamoto Y, Yamada M and Oka M: Identification of ID2 associated with invasion of hepatitis C virusrelated hepatocellular carcinoma by gene expression profile. Int J Oncol 29: 1445-1451, 2006.
16. Chan DW, Lee JM, Chan PC and Ng IO: Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells. Int J Cancer 123: 1043-1052, 2008.
17. Liew CT, Li HM, Lo KW, Leow CK, Chan JY, Hin LY, Lau WY, Lai PB, Lim BK, Huang J, Leung WT, Wu S and Lee JC: High frequency of p16INK4A gene alterations in hepatocellular carcinoma. Oncogene 18: 789-795, 1999.
18. Matsuda Y, Ichida T, Matsuzawa J, Sugimura K and Asakura H: p16(INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology 116: 394-400, 1999.
19. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC and Herman JG: SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 28: 29-35, 2001.
20. Zhang YJ, Ahsan H, Chen Y, Lunn RM, Wang LY, Chen SY, Lee PH, Chen CJ and Santella RM: High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma. Mol Carcinog 35: 85-92, 2002.
21. Yu J, Ni M, Xu J, Zhang H, Gao B, Gu J, Chen J, Zhang L, Wu M, Zhen S and Zhu J: Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer 2: 29, 2002.
22. Schagdarsurengin U, Wilkens L, Steinemann D, Flemming P, Kreipe HH, Pfeifer GP, Schlegelberger B and Dammann R: Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene 22: 1866-1871, 2003.
23. Miyoshi H, Fujie H, Moriya K, Shintani Y, Tsutsumi T, Makuuchi M, Kimura S and Koike K: Methylation status of suppressor of cytokine signaling-1 gene in hepatocellular carcinoma. J Gastroenterol 39: 563-569, 2004.
24. Lehmann U, Berg-Ribbe I, Wingen LU, Brakensiek K, Becker T, Klempnauer J, Schlegelberger B, Kreipe H and Flemming P: Distinct methylation patterns of benign and malignant liver tumors revealed by quantitative methylation profiling. Clin Cancer Res 11: 3654-3660, 2005.
25. Zhang C, Guo X, Jiang G, Zhang L, Yang Y, Shen F, Wu M and Wei L: CpG island methylator phenotype association with upregulated telomerase activity in hepatocellular carcinoma. Int J Cancer 123: 998-1004, 2008.
26. Ma BB, Sung F, Tao Q, Poon FF, Lui VW, Yeo W, Chan SL and Chan AT: The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. Invest New Drugs (In press).
27. Venturelli S, Armeanu S, Pathil A, Hsieh CJ, Weiss TS, Vonthein R, Wehrmann M, Gregor M, Lauer UM and Bitzer M: Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer 109: 2132-2141, 2007.
28. Mosevitsky MI, Capony JP, Skladchikova GY, Novitskaya VA, Plekhanov AYu and Zakharov VV: The BASP1 family of myristoylated proteins abundant in axonal termini: primary structure analysis and physico-chemical properties. Biochimie 79: 373-384, 1997.
29. Carpenter B, Hill KJ, Charalambous M, Wagner KJ, Lahiri D, James DI, Andersen JS, Schumacher V, Royer-Pokora B, Mann M, Ward A and Roberts SG: BASP1 is a transcriptional cosuppressor for the Wilms' tumor suppressor protein WT1. Mol Cell Biol 24: 537-549, 2004.
30. Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE and Reichardt JK: Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354: 975-978, 1999.
31. Nam RK, Toi A, Vesprini D, Ho M, Chu W, Harvie S, Sweet J, Trachtenberg J, Jewett MA and Narod SA: V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology 57: 199-205, 2001.
32. Luo J, Dunn TA, Ewing CM, Walsh PC and Isaacs WB: Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. Prostate 57: 134-139, 2003.
33. Rossi L, Leveri M, Gritti C, De Silvestri A, Zavaglia C, Sonzogni L, Silvestri L, Civardi E, Mondelli MU and Silini EM: Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients. J Hepatol 39: 564-570, 2003.
34. Leon SA, Shapiro B, Sklaroff DM and Yaros MJ: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37: 646-650. 1977.
35. Tokuhisa Y, Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, Tamatsukuri S, Ishitsuka H, Uchida K, Terai S, Sakamoto K, Tamesa T and Oka M: Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma. Br J Cancer 97: 1399-1403, 2007.
36. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD and Knippers R: DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61: 1659-1665, 2001.
37. Ellinger J, Bastian PJ, Haan KI, Heukamp LC, Buettner R, Fimmers R, Mueller SC and von Ruecker A: Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. Int J Cancer 122: 138-143, 2008.
38. Wong IH, Lo YM, Zhang J, Liew CT, Ng MH, Wong N, Lai PB, Lau WY, Hjelm NM and Johnson PJ: Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 59: 71-73, 1999.
39. Wong IH, Zhang J, Lai PB, Lau WY and Lo YM: Quantitative analysis of tumor-derived methylated p16INK4a sequences in plasma, serum, and blood cells of hepatocellular carcinoma patients. Clin Cancer Res 9: 1047-1052, 2003.
40. Wang J, Qin Y, Li B, Sun Z and Yang B: Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients. Clin Biochem 39: 344-348, 2006.
41. Chan KC, Lai PB, Mok TS, Chan HL, Ding C, Yeung SW and Lo YM: Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin Chem 54: 1528-1536, 2008.